Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Owlstone Medical
Owlstone Medical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Regulatory
Owlstone wins contract for disease detection devices
The ‘EXHALE’ project, focused on the early detection of human infection using volatile organic compounds (VOCs) on breath, will develop a handheld device
Finance
Owlstone Medical closes $58m financing round
The funding will be used to advance the company's proprietary platform for early disease detection and precision medicine
Regulatory
Clinical trial launches to develop breath test for multiple cancers
Researchers have launched a clinical trial to develop a breath test, analysing molecules that could indicate the presence of cancer at an early stage
Recruitment
Owlstone Medical appoints Dr Andy Richards to board
Research & Development
Owlstone Medical appoints five experts to Scientific Advisory Board
The additions form a key strategic resource to advise on Breath Biopsy platform, product and study development
Research & Development
Owlstone Medical provides Breath Biopsy Services to AstraZeneca to study disease drivers in Asthma and COPD
Collaboration will explore use of Breath Biopsy to identify novel biomarkers to enable personalised medicine applications
Subscribe now